CN118955258A - Preparation and antimalarial application of 4-O-methylhonokiol - Google Patents
Preparation and antimalarial application of 4-O-methylhonokiol Download PDFInfo
- Publication number
- CN118955258A CN118955258A CN202411172970.XA CN202411172970A CN118955258A CN 118955258 A CN118955258 A CN 118955258A CN 202411172970 A CN202411172970 A CN 202411172970A CN 118955258 A CN118955258 A CN 118955258A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- methyl
- antimalarial
- magnolol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000003430 antimalarial agent Substances 0.000 title claims abstract description 11
- QVLJMPBNVQXYEL-UHFFFAOYSA-N 4-O-methylhonokiol Natural products COC1=CC=C(CC=C)C=C1C1=CC=C(O)C(CC=C)=C1 QVLJMPBNVQXYEL-UHFFFAOYSA-N 0.000 title claims abstract description 8
- OQFHJKZVOALSPV-UHFFFAOYSA-N 4-o-methylhonokiol Chemical compound C1=C(CC=C)C(OC)=CC=C1C1=CC(CC=C)=CC=C1O OQFHJKZVOALSPV-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 230000000078 anti-malarial effect Effects 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 244000042430 Rhodiola rosea Species 0.000 abstract description 11
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 7
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 241001165494 Rhodiola Species 0.000 description 11
- 239000003208 petroleum Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 241000224016 Plasmodium Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000083902 Rhodiola sachalinensis Species 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- JVPLOXQKFGYFMN-UHFFFAOYSA-N gold tin Chemical compound [Sn].[Au] JVPLOXQKFGYFMN-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/34—Separation; Purification; Stabilisation; Use of additives
- C07C41/36—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/34—Separation; Purification; Stabilisation; Use of additives
- C07C41/38—Separation; Purification; Stabilisation; Use of additives by liquid-liquid treatment
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一个3,3’‑新木脂素类化合物4‑O‑甲基和厚朴酚的制备及其在制备抗疟产品中的应用，属于中药、天然药物制药领域。以本发明化合物4‑O‑甲基和厚朴酚为活性成分的抗疟药物。本发明拓展了长鞭红景天中3,3’‑新木脂素类化合物的药用价值。The present invention relates to the preparation of a 3,3'-neolignan compound 4-O-methylhonokiol and its application in the preparation of antimalarial products, belonging to the field of traditional Chinese medicine and natural medicine. An antimalarial drug with the compound 4-O-methylhonokiol as an active ingredient. The present invention expands the medicinal value of 3,3'-neolignan compounds in Rhodiola rosea.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicine and natural medicine pharmacy, and particularly relates to preparation of a3, 3' -neolignan compound 4-O-methyl and magnolol, a medicine composition taking the compound as an active ingredient and application of the compound in antimalarial agents.
Background
Rhodiola rosea (Rhodiola fastigiate (hook. F. Et thoms.) S.H. Fu), rhodiola rosea, rhodiola erecta, rhodiola sachalinensis, which belongs to Rhodiola (Rhodiola), is a perennial herb, and is a whole herb medicine; the plant is produced in Tibet, yunnan, sichuan and other places in China, and is also distributed in the areas of Keshmil, nepal, tin gold and Sur's own in high mountain gravels with an altitude of 2500-5400 m. The rhodiola rosea is recorded in Sichuan Tibetan medicine Standard (2020 edition) and is astringent, sweet, bitter and cool in nature; has effects in clearing away heat and benefiting lung, and can be used for treating lung heat, tracheitis, and halitosis caused by common cold. It is recorded in "Yunnan Chinese medicine resource directory" and has the effect of treating traumatic injury. The literature reports that rhodiola rosea can also treat blood stasis, swelling and trauma （Application of microscopy in authentication of traditional Tibetan medicinal plants of five Rhodiola (Crassulaceae) alpine species by comparative anatomy and micromorphology. Microscopy Research and Technique, 2008, 71(6): 448-458）., the chemical components of rhodiola rosea are less researched in recent years, and the pharmacological activity of rhodiola rosea is also less researched. Modern pharmaceutical researches show that rhodiola rosea contains various chemical components such as organic phenolic acids, glycosides, flavonoids, volatile oil, steroids, trace elements and the like, wherein part of the chemical components have the effects of delaying body aging, scavenging free radicals, preventing and treating senile diseases, resisting oxidation, fatigue, bacteria, viruses, regulating immunity and the like (the research profile of rhodiola rosea). However, there has been no report so far of antimalarial activity of rhodiola rosea and the compound 4-O-methyl and magnolol therein.
Disclosure of Invention
The invention aims to provide a preparation method of a3, 3' -neolignan compound 4-O-methyl and magnolol, a pharmaceutical composition taking the compound as an active ingredient and application of the compound in preparation of antimalarial agents.
The above object of the present invention is achieved by the following technical solutions:
3,3' -neolignan compound 4-O-methyl and magnolol shown in the following structures,
。
The preparation method of 4-O-methyl honokiol comprises taking root or rhizome or whole plant of Rhodiola (Rhodiola), directly cold soaking or hot reflux extracting with organic solvent petroleum ether or chloroform or ethyl acetate or acetone or methanol or ethanol or water, or extracting with above organic solvent or water-cooling or reflux extracting, extracting with petroleum ether or ethyl acetate to obtain total extract, and repeatedly subjecting the total extract to column chromatography to obtain compound 4-O-methyl honokiol.
The preparation method of the compound 4-O-methyl and magnolol is more specifically as follows:
a: extracting root, rhizome or whole plant of rhodiola plant with acetone, methanol, ethanol, water or under reflux to obtain total extract, extracting with petroleum ether or ethyl acetate to obtain corresponding extract, and repeatedly subjecting to column chromatography to obtain compound 4-O-methyl and magnolol.
B: extracting the crude powder of root or rhizome or whole plant of rhodiola plant with organic solvent (such as methanol, ethanol, acetone, ethyl acetate, petroleum ether, and chloroform) directly by cold soaking or hot reflux to obtain total extract, and repeatedly subjecting the total extract to column chromatography to obtain compound 4-O-methyl and magnolol.
More specifically, the preparation method of the compound 4-O-methyl and magnolol comprises the steps of drying roots or rhizomes or whole plants of rhodiola plants in shade, crushing the roots or rhizomes or whole plants to 20-30 meshes, leaching the rhodiola plants with 95% ethanol for 3 times at room temperature, each time for 24h, merging extracting solutions, concentrating the extracting solutions under reduced pressure to obtain extractum, extracting the extractum by using petroleum ether or ethyl acetate as an extraction solvent by a solid-phase extraction method or a liquid-liquid extraction method to obtain corresponding extracts, dissolving the extracted parts by using a proper amount of chloroform/acetone, mixing the samples with 80-100 meshes of silica gel, then carrying out column chromatography with 200-300 meshes of silica gel for dividing and coarse separation, carrying out gradient elution by using petroleum ether/ethyl acetate 100:1-50:1 or petroleum ether/acetone 100:1-50:1, carrying out thin-layer chromatography detection and merging to obtain 9 components, and carrying out repeated silica gel column chromatography, MCI column chromatography and Sephax LH-20 column chromatography on the component 8 to obtain the compound 4-O-methyl and magnolol.
Antimalarial agents containing the compound 4-O-methyl and magnolol and conventional adjuvants.
A pharmaceutical composition comprising a therapeutically effective amount of the compound 4-O-methyl and magnolol and a pharmaceutically acceptable carrier.
The use of the compound 4-O-methyl and magnolol in the preparation of antimalarial agents.
The invention relates to a pharmaceutical composition for resisting malaria, which comprises a compound 4-O-methyl and magnolol and a pharmaceutically acceptable carrier.
The pharmaceutically acceptable carrier in the pharmaceutical composition of the invention refers to a conventional pharmaceutical carrier in the pharmaceutical field. The compounds of the present invention may be administered to a patient in need of such treatment in the form of a composition by oral, nasal inhalation, rectal or parenteral administration. For oral administration, it can be formulated into conventional solid preparations such as tablet, powder, granule, capsule, etc., and liquid preparations such as oil suspension, syrup, elixir, etc.; for parenteral administration, it can be formulated into injectable solutions, etc. Preferred forms are tablets, capsules and injections.
The various dosage forms of the pharmaceutical composition of the present invention can be prepared according to conventional production methods in the pharmaceutical field. For example by mixing the active ingredient with one or more carriers and then forming it into the desired dosage form.
The pharmaceutical composition of the present invention preferably contains 0.1 to 99.5% by weight of active ingredient, most preferably 0.5 to 95% by weight of active ingredient.
The amount of the compound of the present invention to be administered may vary depending on the route of administration, age, weight of the patient, type and severity of the disease to be treated, etc., and the daily dose thereof may be 0.01 to 10 mg/kg body weight, preferably 0.1 to 5 mg/kg body weight. Can be administered one or more times.
The compounds of the invention show a better antimalarial activity.
The invention screens antimalarial activity of the compound 4-O-methyl and magnolol, and the compound shows better antimalarial activity. In antimalarial active applications, the compounds 4-O-methyl and magnolol are applied to a substrate or a population in an amount ranging from 1 to 1000 μm, preferably from 10 to 200 μm, optionally in combination with a carrier and/or medium.
Detailed Description
The following examples of the invention are intended to further illustrate the nature of the invention so that it may be more fully understood by those skilled in the art, but are not intended to limit the invention in any way.
Example 1:
the invention relates to the extraction, separation and purification of a compound 4-O-methyl and magnolol:
Drying the whole plant (9.36 kg) of rhodiola rosea, pulverizing to 20-30 meshes, leaching with 95% ethanol for 3 times at room temperature, each time 50L and 24h, mixing the extracts, concentrating under reduced pressure to obtain extract, performing solid phase extraction with petroleum ether to obtain petroleum ether extract (22.5 g), dissolving the petroleum ether extract with appropriate amount of chloroform/acetone, mixing with 80-100 meshes of silica gel, performing column chromatography with about 10 times of sample amount of silica gel 200-300 meshes, performing gradient elution with petroleum ether/ethyl acetate 100:1-50:1, identifying and combining 9 components by thin layer chromatography, and performing repeated silica gel column chromatography on the component 8 to obtain the compound 4-O-methyl and magnolol.
Example 2:
Physical and spectroscopic data for the compound 4-O-methyl and magnolol of the invention:
4-O-methyl honokiol: yellow oily liquid .1H-NMR (400 MHz, CDCl3) δ: 7.29 (1H, dd, J = 8.3, 2.3 Hz, H-4'), 7.23 (1H, d, J = 2.3 Hz, H-6'), 7.05 (1H, dd, J = 8.1, 2.2 Hz, H-2), 7.03 (1H, d, J = 2.2Hz, H-6), 6.96 (1H, d, J = 8.3 Hz, H-3'), 6.91 (1H, d, J = 8.1 Hz, H-3), 5.92-6.06 (2H, m, H-8, H-8'), 5.04-5.15 (5H, m, H-9, H-9' ,2'-OH), 3.38 (3H, s, 4-OMe), 3.44 (2H, d, J = 6.7 Hz, H-7), 3.35 (2H, d, J = 6.7 Hz, H-7');13C-NMR (100 MHz, CDCl3) δ: 129.1 (s, C-1), 130.6 (d, C-2), 128.9 (d, C-3), 157.1 (s, C-4), 129.9 (s, C-5), 128.0 (d, C-6), 34.4 (t, C-7), 136.6 (d, C-8), 115.7 (t, C-9), 127.9 (s, C-1'), 150.9 (s, C-2'), 111.1 (d, C-3'), 115.6 (d, C-4'), 132.2 (s, C-5'), 130.3 (d, C-6'), 39.6 (t, C-7'), 137.9 (d, C-8'), 116.0 (t, C-9'), 55.7 (s, 4-OMe).
Example 3:
Detection of antimalarial Activity of the compounds of the invention:
The compounds of the invention were evaluated in vitro for their activity against plasmodium falciparum (Plasmodium falciparum D7) using the SYBR Green I method. Plasmodium is cultured in RPMI 1640 medium with 2% human red blood cell packed volume at 37℃, CO 2% concentration. The plasmodium used in the experiment is synchronized to the cycle period by 5% sorbitol, and the infection rate of the plasmodium in the final detection system is 1% and the hematocrit is 2%. After co-culturing the above-mentioned ring-phase plasmodium and test compound in 96-well plate for 72 h, adding fluorescent dye SYBR Green I. Finally, the plasmodium growth was detected by measuring the fluorescence value (excitation: 485 nm, emission: 535: nm) by means of an enzyme-labeled instrument. The inhibition rate is calculated according to the following formula:
plasmodium inhibition (%) = (negative control group fluorescence value-test sample group fluorescence value)/(negative control group fluorescence value-blank group fluorescence value) ×100%.
The activity data are shown in Table 1.
Example 4:
tablet: the compounds obtained in examples 1 and 2 were 4-O-methyl and magnolol 10 mg, lactose 180 mg, starch 55 mg, magnesium stearate 5 mg;
The preparation method comprises the following steps: mixing the compound, lactose and starch, uniformly wetting with propylene glycol, sieving the wetted mixture, drying, sieving again, adding magnesium stearate, tabletting the mixture, and each tablet having a weight of 250 mg and a compound content of 10 mg.
Example 5:
Ampoule agent: the compound 4-O-methyl and magnolol 2 mg obtained in examples 1 and 2;
The preparation method comprises the following steps: the compound 4-O-methyl and magnolol obtained in examples 1 and 2 were dissolved in 3mL propylene glycol, and the resulting solution was filtered and filled into ampoules under aseptic conditions.
Example 6:
The capsule comprises the following components: the compounds obtained in examples 1 and 2 were 4-O-methyl and magnolol 10 mg, lactose 187 mg, magnesium stearate 3 mg;
The preparation method comprises the following steps: mixing the compound with adjuvants, sieving, mixing, and encapsulating the obtained mixture into hard gelatin capsules, each capsule having weight of 200 mg and active ingredient content of 10 mg.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411172970.XA CN118955258A (en) | 2024-08-26 | 2024-08-26 | Preparation and antimalarial application of 4-O-methylhonokiol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411172970.XA CN118955258A (en) | 2024-08-26 | 2024-08-26 | Preparation and antimalarial application of 4-O-methylhonokiol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118955258A true CN118955258A (en) | 2024-11-15 |
Family
ID=93387238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411172970.XA Pending CN118955258A (en) | 2024-08-26 | 2024-08-26 | Preparation and antimalarial application of 4-O-methylhonokiol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118955258A (en) |
-
2024
- 2024-08-26 CN CN202411172970.XA patent/CN118955258A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104341430B (en) | A kind of soil Radix Glycyrrhizae A and extracting method thereof and purposes | |
| CN104257715B (en) | Herba Artemisiae extract and its preparation method and application | |
| CN105198854A (en) | Preparation method and application of isopentene alkenylation flavonoid compound with nerve protection effect | |
| CN105820147A (en) | Preparation method and application of active ingredients of artemisia rupestris | |
| CN105801396B (en) | Diterpene enantiomeric compounds and its preparation method and application | |
| CN109912551B (en) | Eudesmane sesquiterpene compound and pharmaceutical composition, preparation method and application thereof | |
| EP2221058B1 (en) | Antimelancholic medicine prepared with jujube camp materials | |
| CN105131008B (en) | Preparation method and application of prenylated flavonoid compound with anti-hepatoma activity | |
| CN107837301B (en) | Piper laetispicum extract and preparation method and application thereof | |
| CN105669611A (en) | Novel ring farnesane type sesquiterpenes compound and preparation method and medical application thereof | |
| CN103788143B (en) | 1-O-ethyl-6-O-caffeoyl-β-D-glucopyranoside and its pharmaceutical composition and application | |
| CN118955258A (en) | Preparation and antimalarial application of 4-O-methylhonokiol | |
| CN113754620B (en) | Lignan amide compound in fructus cannabis, and preparation method and application thereof | |
| CN118955435A (en) | Preparation and antimalarial application of a 7,7'-epoxylignan | |
| CN118955590A (en) | Preparation and antimalarial application of herbicide-8-O-glucuronide methyl ester | |
| CN109810153B (en) | Preparation method and analgesic application of aromatic substituted glucose compound and pharmaceutical composition thereof | |
| CN109206392B (en) | Coumarin compound and preparation method and application thereof | |
| CN113754622B (en) | Lipid lowering application of dibenzofuran compounds | |
| CN118126050B (en) | 6-Methoxy carbazole alkaloid compound and preparation method and application thereof | |
| CN115611796B (en) | Menthol monoterpene dimer cyhalothanol B and application thereof in preparation of antitumor drugs | |
| CN114957272B (en) | A kind of chromanane dimer and its preparation method and application | |
| CN118955449B (en) | Sesquiterpenoids in syringa oblonga, and preparation method and application thereof | |
| CN118930420B (en) | A sesquiterpenoid compound and its preparation method and application | |
| CN114031625B (en) | Preparation and application of compound with colorectal cancer resisting activity in liquorice | |
| CN104288169B (en) | A kind of flavonoid glycoside compound and its production and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |